Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 1
Submit an article Journal homepage
222
Views
48
CrossRef citations to date
0
Altmetric
Review

Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors

Tomi K Sawyer ARIAD Pharmaceuticals, Cambridge, MA 02139, USA. [email protected]
Pages 1-19 | Published online: 02 Mar 2005

  • BOGENRIEDER T, HERLYN M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 22:6524–6536.
  • ••Excellent review describing the intimatemechanisms contributing to cancer metastasis.
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
  • ••Excellent review describing the intricatenetwork of biological activities that are orchestrated in various types of cancers.
  • MACALUSO M, PAGGI MG, GIORDANO A: Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene (2003) 22:6472–6478.
  • PONDER BAJ: Cancer genetics. Nature (2001) 411:336–341.
  • NYGREN P, LARSSON R: Overview of the clinical efficacy of investigational anticancer drugs. J. Internal Med. (2003) 251:46–75.
  • CHAMBERS AF, GROOM AC, MACDONALD IC: Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer (2002) 2:563–572.
  • KAUFFMAN EC, ROBINSON VL, STADLER WM, SOKOLOFF MH, RINKER-SCHAEFFER CW: Metastases suppression: the evolving role of metastases suppressor genes for regulating cancer cell growth at the secondary site. J. Urology (2003) 169:1122–1133.
  • WOODHOUSE EC, CHUAQUI RF, LIOTTA LA: General mechanisms of metastasis. Cancer (1997) 80:1529–1537.
  • FIDLER LJ: Critical determinants of cancer metastasis: rational for therapy. Cancer Chemother. Pharmacol. (1999) 43:S3–S10.
  • WYCKOFF JB, JONES JG, CONDEELIS JS, SEGALL JE: A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. (2000) 60:2504–2511.
  • FIDLER LJ: Orthotopic implantation of human colon carcinomas into nude mice provides valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. (1991) 15:272–306.
  • KOHN EC, LIOTTA LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. (1995) 55:1856–1862.
  • RADINSKY R, ELLIS LM: Molecular determinants in the biology of liver metastasis. Surg. Oncol. Clin. North Am. (1996) 5:215–229.
  • MUNDY GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer (2002) 2:584–593.
  • ••Excellent review describing bone metastasisand therapeutic strategies.
  • HOFFMAN RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs (1999) 17:343–359.
  • CHAMBERS AF, MACDONALD IC, SCHMIDT EE, MORRIS VL, GROOM AC: Clinical targets for anti-metastasis therapy. Adv. Cancer Res. (2000) 79:91–121.
  • THOMAS SM, BRUGGE JS: Cellular functions regulated by Src family kinases. Ann. Rev. Cell. Dev. Biol. (1997) 13:513–609.
  • BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2002) 411:355–365.
  • ••Excellent review describing the molecularaspects of oncogenic protein kinases at the genetic and cellular levels.
  • DONG Tr, LAMB PW, RINKER-SCHAEFFER CW et al.: KAI1, a metastasis suppressor gene for prostate cancer on human chromasome 11p11.2. Science (1995) 12:884–886.
  • MORRIS VL, SCHMIDT EE, KOOP S et al.: Effects of the disintegrin erisostatin on individual steps of hematogeneous metastasis. Exp. Cell Res. (1995) 219:571–578.
  • HERYNK MH, RADINKSKY R: The coordinated functional expression of epidermal growth factor receptor and c-Met in colorectal carcinoma metastasis. In Vivo (2000) 14:587–596.
  • DE MARZO AM, KNUDSEN B, CHAN-TACK K, EPSTEIN JI: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology (1999) 3:707–713.
  • GAO AC, LOU W, DONG JT, ISAACS JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. (1997) 57:846–849.
  • YOSHIDA BA, DUBAUSKAS Z, CHEKMAREVA MA, CHRISTIANO TR, STADLER WM, RINDKER- SCHAFFER CW: Mitogen-activated protein protein 4/stress-activated protein/ Erc kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. (1999) 59:5483–5487.
  • KONISHI N, NAKAOKA S, TSUZUKI T et al.: Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn. J. Cancer Res. (1993) 84:1050–1054.
  • LEE JH, WELCH DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. (1997) 57:2384–2387.
  • LEE JH, MIELE ME, HICKS DJ et al.: KiSS-I, a novel human malignant melanoma metastasis-suppressor gene. J. Nod Cancer Inez (1996) 88:1731–1777.
  • HABERMANN H, RAY V, HABERMANN W, PRINS GS: Alterations in gap junction protein expression I human benign prostatic hyperplasia and prostate cancer. J. UroL (2002) 167:655–660.
  • NAUMOV GN, WILSON SM, MACDONALD IC et al.: Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy to monitor steps in tumor metastasis. J. Cell Sci. (1999) 112:1835–1842.
  • KUO TH, KUBOTA T, WATANABE M et al.: Liver colonization competence governs colon cancer metastases. Proc. Nail. Acad. Sci. USA (1995) 92:12085–12099.
  • HAHN WC, WEINBERG RA: Modelling the molecular circuitry of cancer. Nat. Rev. Cancer (2002) 2:331–341.
  • NAM NH, PARANG K: Current targets for anticancer drug discovery. Curr. Drug Targets (2003) 4:159–179.
  • EBRALIDZE A, TULCHINSKY E, GRIGORIAN M et al.: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to Ca2*-binding protein family. Gene Dev. (1989) 3:1086–1093.
  • DEAR TN, RAMSHAW IA, KEFFORD RF: Differential expression of a novel gene, WDNM I, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res. (1988) 48:5203–5209.
  • DEAR TN, MCDONALD DA, KEFFORD RF: Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8 cells. Cancer Res. (1989) 49:5323–5328.
  • BASSETT P, BELLOCQ JP, WOLF C et al.: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinoma. Nature (1990) 348:699–704.
  • FUJITA M, SPRAY DC, CHOI H et aL: Extracellular matrix regulation of cell-cell communication and tissue-specific gene expression in primary liver cultures. Prog. Clin. BioL Res. (1986) 226:333–360.
  • XIA W, UNGER P, MILLER L, NELSON J, GELMAN IH: The Src-suppressed C kinase substrate SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. (2001) 61:5644–5651.
  • MIYAKE M, INUFASA H, ADACHI M et aL: Suppression of pulmonary metastasis using adenovirally motility related protein-I (MRP-I/CD9) gene delivery. Oncogene (2000) 19:5221–5226.
  • RADFOR KJ, MALLESCH J, HERSEY P: Suppression of human melanoma cell growth and metastasis by the melanoma associated antigen CD63 (ME491). Int. J. Cancer (1995) 62:631–635.
  • NAKAGAWA T, TANAKA S, SUZUKI H et al.: Overexpression of the csk gene suppresses tumor metastasis in vivo. Int. J Cancer (2000) 88:384–391.
  • FU Z, SMITH PC, ZHANG L et cd.: Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Nail. Cancer Inst. (2003) 95:878–889.
  • BISCARDI JS, TICE DA, PARSON SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. (1999) 76:61–119.
  • SCHLESSINGER J: New roles for Src kinases in control of cell survival and angiogensis. Cell (2000) 100:293–296.
  • FRAME MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta (2002) 1602:114–130.
  • BOYCE BF, YONEDA T, LOWE C, SORIANO P, MUNDY GR: Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. Clin. Invest. (1992) 90:1622–1627.
  • XING L, VENGAS AM, CHEN A et aL: Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. (2001) 15:241–253.
  • PERL AK, WILGENBUS P, DAHL U, SEMB H, CHRISTOFORI G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 392:190–193.
  • PAUL R, EWING CM, JARRARD DF, ISAACS WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br. J. UroL (1997) 79(Suppl.):37–43.
  • MBALAVIELE G, DUNSTAN CR, SASAKI A, WILLIAMS PJ, MUNDY GR, YONEDA T: E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastasis in an experimental metastasis model. Cancer Res. (1996) 56:4063–4070
  • DARNELL JE JR: Transcription factors astargets for cancer therapy. Nat. Rev. Cancer (2002) 10:740–749.
  • CLARK EA, GOLUB TR, LANDER ES, HYNES RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature (2000) 406:532–535.
  • AVIZIENYTE E, WYKE AW, JONES RJ et al.: Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat. Cell Biol. (2002) 8:632–638.
  • SAKAMOTO M, TAKAMURI M, INO Y, MIURU A, GENDA T, HIROHASHI S: Involvement of c-Src in carcinoma cell motility and metastasis. Jpn. J. Cancer Res. (2001) 92:941–946.
  • BOYER B, BOURGEOIS Y, POUPON M-R: Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene (2002) 21:2347–2356.
  • HOOD JD, CHERESH DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer (2002) 2:91–100.
  • GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285:1028–32.
  • FELDING-HABERMANN B, O'TOOLE TE, SMITH JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. NatL Acad. Sci. USA (2001) 98:1853–1858.
  • PRUITT K, DER CJ: Ras and Rho regulation of the cell cycle and oncogenes. Cancer Lett. (2001) 171:1–10.
  • BAR-SAGI D: A Ras by any other name. MoL Cell. Biol. (2001) 21:1441–1443.
  • BOS JL: Ras oncogenes in human cancer: a review. Cancer Res. (1989) 49:4682–4689.
  • MALANEY S, DALY RJ: The ras signaling pathway in mammary tumorigenesis and metastasis. J. Mammary Gland Biol. Neoplasia (2001) 6(1):101–113.
  • VARGHESE HJ, DAVIDSON MT, MACDONALD IC et al.: Activated Ras regulates the proliferation/apoptosis balance and early survival of developing micrometastasis. Cancer Res. (2001) 61:887–891.
  • SAHAI E, MARSHALL CJ: Rho-GTPases and cancer. Nat. Rev. Cancer (2002) 2:133–42.
  • MAREEL M, LEROY A: Clinical, cellular and molecular aspects of cancer invasion. PhysioL Rev. (2000) 83:337–376.
  • TAMANOI F, KATO-STANKIEWICZ J, JIANG C, MACHADO I, THAPAR N: Farnesylated proteins and cell cycle progression. J. Cell Biochem. (2001) 37(Suppl.):64–70.
  • MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912–1934.
  • MANNING BD, CANTLEY LC: Hitting the target: emerging technologies in the search for kinase substrates. Sci. STKE (2002) (162):PE49.
  • COLLETT MS, ERIKSON RL: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA (1978) 75:2021–2024.
  • STRAWN LM, SHAWVER LK: Tyrosine kinases in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opin. Investig. Drugs (1998) 7:533–573.
  • TSATSANIS C, SPANDIDOS DA: The role of oncogenic kinases in human cancer. Int. J. Malec. Med. (2000) 5:583–590.
  • COHEN P: Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. (2002) 1:309–315.
  • DREVS J, MEDINGER M, SCHMIDT-GERSBACH C, WEBER R, UNGER C: Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets (2003) 4:113–121.
  • BRUNELLESCHI S, PENEGO L, SANTORO MM, GAUDINO G: Receptor tyrosine kinases as target for anti-cancer therapy. Curr. Pharm. Design (2002) 8:1959–1972.
  • FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. PharmacoL Ther. (2002) 93(2-3):79–98.
  • COHEN GB, REN R, BALTIMORE D: Modular binding domains in signal transduction. Cell (1995) 80:237–248.
  • PAWSON T: Protein modules and signalling networks. (1995) Nature 373:573–580.
  • SAWYER TK, BOHACEK RS, DALGARNO DC et aL: SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini-Rev. Med. Chem. (2002) 2:475–488.
  • CIARDIELLO F, TORTORA G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. (2001) 7:2958–2970.
  • MCLEAN GW, AVIZIENYTE E, FRAME MC: Focal adhesion kinase as a potential target in oncology. Expert Opin. Pharmacother. (2003) 4:227–234.
  • JONES RJ, BRUNTON VG, FRAME MC: Adhesion-linked kinases in cancer, emphasis on src, focal adhesion kinase and PI 3-kinase. Eur. j Cancer (2000) 36:1595–1606.
  • SAWYER T, BOYCE B, DALGARNO, IULIUCCI J: Src inhibitors: genomics to therapeutics. Expert Opin. Investig. Drugs (2001) 10:1327–1344.
  • METCALF CA III, VAN SCHRAVENDIJK MR, DALGARNO DC, SAWYER TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Design (2002) 8:2049–2075.
  • SUSA M, MISSBACH, M, GREEN J: Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends PharmacoL Sci. (2000) 21:489–495.
  • MAA M-C, LEU TH, MCCARLEY DJ, SCHATZMAN RC, PARSONS SJ: Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. NatL Acad. Sci. USA (1995) 92:6981–6985.
  • MAO W, IRBY R, COPPOLA D et al.: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 15:3083–3090.
  • IRBY RB, MAO W, COPPOLA D et aL:Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet (1999) 21:187–190.
  • TALAMONTI MS, ROH MS, CURLEY SA, GALLICK GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91:3–60.
  • VAN OIJEN MG, RIJKSEN G, TEN BROEK FW, SLOOTWEG PJ: Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J. Oral PathoL Med. (1998) 27:147–152.
  • LUTZ MP, ESSE IBIB, FLOSSMANN-KAST BB et al.: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. (1998) 243:503–508.
  • NABEL EG: CDKs and CKIs: molecular targets for tissue remodelling. Nat. Rev. Drug Discov. (2002) 1:587–598.
  • MORGA DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev. Cell. Dev. Biol. (1997) 13:261–291.
  • SIELECKI TM, BOYLAN JF, BENFIELD PA, TRAINOR GL: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. (2000) 43:1–18.
  • KAMB A, GRUIS NA, WEAVER-FELDHAUS J et al.: A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 264:436–440.
  • LI Q, ZHU GD: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Topics Med. Chem. (2002) 2:939–971
  • HILL MM, HEMMINGS BA: Inhibition of protein kinase B/Akt. Implications for cancer therapy. PharmacoL Ther. (2002) 93:243–251.
  • MAYO LD, DONNER DB: The PTEN, Mdrn2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. (2002) 27:462–467.
  • VIVANCO I, SAWYERS CL: The phosphoinositide 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2:489–501.
  • YOGANATHAN N, YEE A, ZHANG Z et al.: Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. PharmacoL Ther. (2002) 93:233–242.
  • LOS M, BUREK CJ, STROH C, BENEDYK K, HUG H, MACKIEWICZ A: Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today (2003) 8:67–77.
  • STEIN RC: Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer (2001) 8:237–248.
  • CHEN J, FANG Y: A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem. PharmacoL (2002) 64:1071–1077.
  • HIDALGO M, ROWINSKI EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000)19:6680–6686.
  • HUANG S, HOUGHTON PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs (2002) 3:295–304.
  • MAGEE T, MARSHALL C: New insights into the interaction of Ras with the plasma membrane. Cell (1999) 98:9–12.
  • KERKHOFF E, RAPP UR: Cell cycle targets of Ras/Raf signalling. Oncogene (1998) 17:1457–1462.
  • WEINSTEIN-OPPENHEIMER CR, BLALOCK \In., STEELMAN LS, CHANG F, MCCUBREY JA: The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther. (2000) 88:229–279.
  • NOTTAGE M, SIU LL: Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr. Pharm. Des. (2002) 8:2231–2242.
  • DAVIES H, BIGNELL GR, COX C et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417:949–954.
  • JOHNSON GL, LAPADAT R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 298: 1911-1912.
  • KATSANAKIS KD, OWEN C, ZOUMPOULIS V: JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. Anticancer Res. (2002) 22:755–759.
  • FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. OncoL (2000) 29:15–19.
  • RELF M, LEJEUNE S, SCOTT PA et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57:963–969.
  • TAYLOR AP, OSORIO L, CRAIG R et aL: Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin. Cancer Res. (2002) 8:1213–1222.
  • NABESHIMA K, INOUE T, SHIMAO Y, SAMESHIMA T: Matrix metalloproteinases in tumor invasion: role for cell migration. PathoL Intern. (2002) 52:255–264.
  • CHANG C, WERB Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell. Biol. (2001) 11:S37–S43.
  • JIANG Y, GOLDBERG ID, SHI YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene (2001) 21:2245–2252.
  • GIANNELLI G, ASTIGIANO S, ANTONACI S et al.: Role of a3131 and a634 integrins in tumor invasion. Clin. Exp. Metastasis (2002) 19:217–223.
  • KUMAR CC: Integrin avI33 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets (2003) 4:123–131.
  • ALBELDA SM, METTE SA, ELDER DE et al.: Integrin distribution in malignant melanoma: association of the 133 subunit with tumor progression. Cancer Res. (1990) 50:6757–6764.
  • LIAPIS H, FLATH A, KITAZAWA S: Integrin a433 expression by bone-residing breast cancer metastases. Diagn. MoL PathoL (1996) 5:27–135.
  • PECHEUR I, PEYRUCHAUD 0, SERRE C-M et aL: Integrin avI33 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB (2002) 16:1266–1268.
  • TETI A, MIGLIACCIO S, BARON R: The role of the avI33integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcified Tissue Intern. (2002) 71:293–299.
  • TUCKER GC: Inhibitors of integrins. Curr. Opin. PharmacoL (2002) 2:394–402.
  • COLEMAN RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. (2001) 27:165–176.
  • O'KEEFE, RJ, SCHWARZ EM, BOYCE BF: Bone metastasis: an update on mechanisms of bone resorption and therapeutic strategies. Curr. Opin. Orthoped. (2000) 11:353–359.
  • SOUTHBY J, KISSIN MW, DANKS JA et al.: Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. (1990) 50:7710–7716.
  • POWELL GJ, SOUTHBY J, DANKS JA et al.: Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared to other sites. Cancer Res. (1991) 51:3059–3061.
  • BRYDEN AA, HOYLAND JA, FREEMONT AJ, CLARKE NW, GEORGE NJ: Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastasis. Br .j Cancer (2002) 86:322–325.
  • MIKI T, YANO S, HANBUCHI M, SONE S: Bone metastasis model with multiorgan dissemination of human small-cell lung cancer. OncoL Res. (2001) 12:209–217.
  • ZHANG QX, BORG A, WOLF DM, OESTERREICH S, FUQUA SA: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. (1997) 57:1244–1249.
  • DE LARCO JE, WUERTZ BR, ROSNER KA al.: A potential role for IL-8 in the metastatic phenotype of breast carcinoma cells. Am.. J Pathol. (2001) 158:639–646.
  • DOWNEY SE, HOYLAND J, FREEMONT AJ, KNOX F, WALLS J, BRUNDRED NJ: Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J. PathoL (1997) 183:212–217.
  • GUISE TA, YIN JJ, TAYLOR SD et aL: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Clin. Invest. (1996) 98:1544–1549.
  • GALLWITZ WE, GUISE TA, MUNDY GR: Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. Clin. Invest. (2002) 110:1559–1572.
  • BENDRE MS, GADDY-KURTEN D, MON-FOOTE T et al.: Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. (2002) 62:5571–5579.
  • THOMAS RJ, GUISE TA, YIN JJ et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 140:4451–4458.
  • NELSON JB, NABULISI AA, VOGELZANG NJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944–949.
  • GUISE TA, YIN JJ, MOHAMMED KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 97:779–784.
  • HARRIS SE, BONEWALD LF, HARRIS MA et al.: Effects of transforming growth factor-I3 on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type 1 collagen mRNA in longterm cultures of fetal rat calvarial osteoblasts. J Bone Min. Res. (1994) 9:855–863.
  • DAWSON NA: Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr. Opin. UroL (2002) 12:413–418.
  • GREEN JR, CLEZARDIN P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. OncoL (2002) 25(6 Suppl. 1):53–59.
  • SASAKI A, BOYCE BF, STORY B et al.: Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res. (1995) 55:3551–3557.
  • DIEL IF, SOLOMAYER EF, COSTA SD et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N EngL J. Med. (1998) 339:357–363.
  • CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118–129.
  • ELLIS LM: A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg. (2003) 69:3–10.
  • LEYLAND-JONES B: Trastuzumab: hopes and realities. Lancet OncoL (2002) 3:137–144.
  • GRETEN TF, JAFFEE EM: Cancer vaccines./ Clin. OncoL (1999) 17:1047–1060.
  • TAMM I, KORKEN B, HARTMANN G: Antisense therapy in oncology: new hope for an old idea? Lancet (2001) 358:489–497.
  • WANG H, PRASAD G, BUOLAMWINI JK, ZHANG R: Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets (2001) 1:177–196.
  • MCCORMICK F: Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer (2001) 1:130–141.
  • BYKOV FJN, ISSAEVA N, SHILOV A et al.: Restoration of tumor suppressor function to mutant p53 by a low-molecular weight compound. Nat. Med (2002) 8:282–288.
  • AINA OH, SROKA TC, CHEN ML, LAM KS: Therapeutic cancer targeting peptides. Biopolymers (2002) 66:184–199.
  • BRUMMELKAMP TR, BERNARDS R: New tools for functional mammalian cancer genetics. Nat. Rev. Cancer (2003) 3:781–788.
  • ANZICK SL, TRENT JM: Role of genomics in identifying new targets for cancer therapy. Oncology (2002) 16(5 Suppl. 4):7–13.
  • HANASH S: Disease proteomics. Nature (2003) 422:226–232.
  • DANCEY J, SAUSVILLE EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. (2003) 2:296–313.
  • FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. PharmacoL Ther. (2002) 93:79–98.
  • DE BONO JS, ROWINSKY EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. (2002) 64:227–254.
  • ZHU Z, BOHLEN P, WITTE L: Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets (2002) 2:135–156.
  • BASELGA J, HAMMOND LA: HER-targeted tyrosine-kinase inhibitors. Onco/ogy (2002) 63\(Suppl. 1):6–16.
  • RANSON M, SLIWKOWSKI MX: Perspectives on anti-HER monoclonal antibodies. Onco/ogy (2002) 63\(Suppl. 1):17–24.
  • LIPTON A, SMALL E, SAAD F et al.: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to parnidronate. Cancer Invest. (2002) 20\(Suppl. 2):45–54.
  • LIPTON A: Bone metastases in breast cancer. Curr. Treat. Options OncoL (2003) 4:151–158.
  • GIANNI L: The future of targeted therapy: combining novel agents. Oncology (2002) 63\(Suppl. 1):47–56.
  • HALUSKA P, DY GK, ADJEI AA: Farnesyl transferase inhibitors as anticancer agents. Eur. Cancer (2002) 38:1685–1700.
  • OHKANDA J, KNOWLES DB, BLASKOVICH MA, SEBTI SM, HAMILTON AD: Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. (2002) 2:303–323
  • JOHNSTON SR: Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet OncoL (2001) 2:18–26.
  • SEBOLT-LEOPOLD JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene (2000) 19:6594–6599.
  • HIRTE HW, VERGOTE IB, JEFFREY JR et al.: An international multicentre Phase III study of BAY 12–9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy. Proc. Am. Soc. Clin. OncoL (2001) 20:A843 (Abstract).
  • EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer (2002) 2:161–174.
  • SPARANO JP, BERNARDO P, GRADISHAR WJ, INGLE JN, ZUCKER S, DAVIDSON NE: Randomized Phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. OncoL (2002) 21:A173 (Abstract).
  • KING J, CLINGAN P, MORRIS DL: Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastasis (CRCLM): significant survival advantage in patients with muscoloskeletal symptoms. Proc. Am. Soc. Clin. OncoL (2002) 21:A537 (Abstract).
  • BRAMHALL SR, ROSEMURGY A, BROWN PD, BOWRY C, BUCKELS JAG: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. OncoL (2001) 19:2447–3455.
  • YANG JC, HAWORTH I, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. OncoL (2002) 21:A15 (Abstract).
  • GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avI33. Clin. Cancer Res. (2000) 6:3056–3061.
  • VOEST EE, BEEREPOOT LV, GROENEWEGAN Get al.: Phase I trial of recombinant angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc. Am. Soc. Clin. OncoL (2002) 21:A322 (Abstract).
  • HERBST RS, HESS KR, TRAN HT et al.: Phase I study of recombinant human endostatin in patients with advanced solid tumors./ Clin. OncoL (2002) 20:3792–3803.
  • POWLES T, PATERSON S, KANIS JA et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. OncoL (2002) 20:3219–3124.
  • FREIJE JM, BALBIN M, PENDAS AM, SANCHEZ LM, PUENTE XS, LOPEXZ-OTIN C: Matrix metalloproteinases and tumor progression. Adv. Exp. Med. Biol. (2003) 532:91–107.
  • HEIKKILA P, TERONEN 0, HIRU MY et al.: Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J. Surg. Res. (2003) 111:45–52.
  • CLEZARDIN P, FOURNIER P, BOISSIER S, PEYRUCHAUD 0: In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. (2003) 10:173–180.
  • OADES GM, SENARTNE SG, CLARKE IA, KIRBY RS, COLSTON KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevolonate pathway, impairing Ras membrane localization. J UroL (2003) 170:246–252.
  • DENOYELLE C, HONG L, VANNIER JP, SORIA C: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and independent effects. Br. J Cancer (2003) 88:1631–1640.
  • DRUKER BJ: 5TI571 (Gleevec/Glivec, imatinib) versus interferon + cytarabine as initial therapy for patients with CML. Results of a randomized study. Proc. Am. Soc. Clin. OncoL (2002) 21:A1.
  • CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, MATTER A: Glivec (5TI571, Imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Disc. (2002) 1:493–502.
  • BASELGA J, TRIGO JM, BOUHRIS J et al.: Cetuximab (C225) plus cisplatin/ carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same does and schedule platinum-based regimen. Proc. Am. Soc. OncoL (2002) 21:A900 (Abstract).
  • BURTNESS BA, FLOOD YLW, MATTAR BI, FORASTIERE AA: Phase III trial comparing cisplatin (C) + placebo (P) + epidermal growth factor receptor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc. Am. Soc. Clin. OncoL (2000) 21:A901 (Abstract).
  • SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. EngL J Med (2001) 344:783–792.
  • FUKUOKA M, YANO S, GIACCONE G et al.: Final results from a Phase II trial of ZD1839 ('Iressd) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. OncoL (2002) 21:A1188 (Abstract).
  • NATALE RB, SKARIN A, MADDOX AM et al.: Improvement in symptoms and quality of life from advanced non-small cell lung cancer patients receiving ZD1839 ('Iressd) in IDEAL 2. Proc. Am. Soc. OncoL (2002) 21:A1167 (Abstract).
  • WILKINSON E: Surprise Phase III failure for ZD1839. Lancet OncoL (2002) 3:583.
  • HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. OncoL (2001) 19:3267–3279.
  • SUMMY JM, GALLICK GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. (2003) 22:337–358.
  • WANG Y, METCALF CA III, SHAKESPEARE WC et al.: Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. (2003) 13:3067–3070.
  • SUNDARAMOORTHI R, SHAKESPEARE WC, KEENAN TP et aL: Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogs. Bioorg. Med. Chem. Lett. (2003) 13:3063–3066.
  • VU C, LUKE GP, KAWAHATA N et aL: Bone-targeted pyrido [2,3-d] pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Bioorg. Med. Chem. Lett. (2003) 13:3071–3074.
  • BOYCE BF, XING L, SHAKESPEARE W et al.: Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kdney Int. (2003) 85:52–55.
  • SHAKESPEARE W, WANG Y, METCALF C et al.: Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent activity in an animal model of osteolytic bone metastasis. Proc. Am. Acad. Cancer Res. (2003) 44:A3871 (Abstract).
  • BELSCHES-JABLONSKI AP, BISCARDI JS, PEAVY DR, TICE DA ROMNEY DA, PARSONS SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene (2001) 20:14674–1475.
  • MENKE A, PHILIPP C, VOGELMANN R et al.: Down-regulation of E-cadherin gene expression by collagen type I and type II in pancreatic cell lines. Cancer Res. (2001) 61:3508–3517.
  • ELICEIRI BP, PAUL R, SCHWARTBERG PL, HOOD JD, LENG J, CHERESH DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell (1999) 4:915–924.
  • TATTON L, MORLEY GM, CHOPRA R, KHWAJA A: The Src-selective kinase inhibitor PP I also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. (2003) 278:4847–4853.
  • CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: The kinase inhibitor PPI blocks tumorogenesis induced by RET oncogenes. Cancer Res. (2002) 62:1077–1082.
  • NAM JS, INO Y, SAKAMOTO M, HIROHASHI S: Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. (2002) 8:2430–2436.
  • BOSCHELLI DH: 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. (2002) 2:1051–1063.
  • YEZHELYEV M, WAGNER C, KOHL G et al.: In vivo and in vitro effects of a novel Src tyrosine kinase inhibitor on human pancreatic cancer in a nude mouse model. Proc. Am. Acad. Cancer Res. (2003) 44:A1718 (Abstract).
  • KEKHARAM M, NASIR A, KAISER HE, COPPOLA D: Insulin-like growth factor-I receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res. (2003) 23:1517–1524.
  • RECCHIA I, RUCCI N, FESTUCCIA C et al.: Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur. J. Cancer (2003) 39:1927–935.
  • METCALF C III, WANG Y, SHAKESPEARE Wet al.: Discovery of potent and selective Src inhibitors and their development as antitumor and antimetastatic agents. Proc. Am. Acad. Cancer Res. (2003) 44:A1716.
  • O'HARE T, STOFFREGEN EP, ABDULLAH OM et al.: Potent inhibition of Imatinib-resistant variants of Bcr-Abl by a novel dual selective Src/Abl kinase inhibitor AP23464: Implications for CML therapy. Proc. Am. Soc. Hematol. (2003) A59.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.